GGrantIndex
Sort

261,768 grants matching gene therapy

Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)

$1,039,095
Adam Wayne Carrico · University Of Miami School Of Medicine · R01 · FY2022 · MH

A novel immunotolerizing therapy for autoimmune vitiligo

$1,039,086
Kanneganti Murthy · Radikal Therapeutics, Inc. · R44 · FY2017 · AR

Reading mitochondrial apoptotic signaling to identify active cancer therapeutics

$1,038,996
Anthony G Letai · Dana-Farber Cancer Inst · R35 · FY2022 · CA

Colorectal Cancer (CRC) Prevention by Urolithin A in Rodent CRC models

$1,038,958
Margie L. Clapper · Research Inst Of Fox Chase Can Ctr · N01 · FY2023 · CA

RESTORATION OF APOPTOSIS IN CANCER

$1,038,933
University Of Texas Md Anderson Can Ctr · P01 · FY2000 · CA

Therapy for NF1-Related Tumors and other Genetic Tumor Predisposition Syndromes

$1,038,724
Brigitte Widemann · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA

Etiological Studies of Gastric Carcinoma

$1,038,693
Keith T Wilson · Vanderbilt University Medical Center · P01 · FY2017 · CA

Pathway and GWAS SNPs: Role in SCCHN Risk, Outcome and Treatment Response

$1,038,578
Brenda Diergaarde · University Of Pittsburgh At Pittsburgh · P50 · FY2011 · CA

National Center for Canine Models of Duchenne Muscular Dystrophy (NCDMD)

$1,038,570
Joe N Kornegay · Univ Of North Carolina Chapel Hill · U24 · FY2009 · NS

National Center for Canine Models Muscular Dystrophy (NCDMD)

$1,038,570
Joe N Kornegay · Univ Of North Carolina Chapel Hill · U24 · FY2009 · NS

MODEL SYSTEMS TOWARD DEVELOPMENT OF HUMAN GENE THERAPY

$1,038,500
University Of Pittsburgh At Pittsburgh · P01 · FY2003 · DK

Tracking longitudinal change in presymptomatic genetic prion disease (TLC-Pre-gPrD)

$1,038,413
Michael D Geschwind · University Of California, San Francisco · R01 · FY2020 · AG

Signaling in the retina and retinal pigment epithelium

$1,038,271
Thomas Redmond · National Eye Institute · ZIA · FY2019 · EY

CD19-Specific Central Memory T Cell Adoptive Immunotherapy for Non-Hodgkin Lymphoma

$1,038,189
Andrew A. Raubitschek · Beckman Research Institute/City Of Hope · P50 · FY2015 · CA

Targeting SIV macrophage reservoirs in the CNS by CSF1R inhibition

$1,038,147
Woong-Ki Kim · Tulane University Of Louisiana · R01 · FY2023 · MH

A Novel Therapeutic for Liver Fibrosis

$1,038,130
Prakash Narayan · Angion Biomedica Corporation · R44 · FY2013 · AA

Basic and Translational Studies of Cystic Fibrosis

$1,038,005
Raymond A Frizzell · University Of Pittsburgh At Pittsburgh · P30 · FY2017 · DK

SBIR TOPIC 257, INSTRUMENTS AND DEVICES THAT PRESERVE MOLECULAR PROFILES IN TUMO

$1,037,959
Adam Schayowitz · Biomarker Strategies, Llc · N43 · FY2011 · CA

Improved Chimeric Antigen Receptor Therapies B-cell Malignancies

$1,037,952
James Kochenderfer · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

In Vivo Cellular and Molecular Imaging Centers (ICMICs)

$1,037,769
Robert F Mattrey · University Of California, San Diego · P50 · FY2012 · CA

Computational Modeling Core

$1,037,741
Katrina M. Waters · University Of Wisconsin-Madison · U19 · FY2017 · AI

Identifying therapeutic targets that confer synaptic resilience to Alzheimer's disease

$1,037,676
Jeremy H. Herskowitz · University Of Alabama At Birmingham · R01 · FY2019 · AG

Neuroengineering a Robust Vocal Learning Phenotype in Mice as a Model for Treating Communication Disorders

$1,037,645
Erich D Jarvis · Rockefeller University · R01 · FY2019 · DC

A two-pronged approach to generating novel models of photoreceptor degeneration for regenerative cell therapy

$1,037,547
Yingbin Fu · Baylor College Of Medicine · U24 · FY2021 · EY

Virus and olfactory system interactions accelerate Alzheimer's disease pathology

$1,037,518
Diego Restrepo · University Of Colorado Denver · R01 · FY2023 · AG